Nimbus Therapeutics reported positive Phase IIb results on Wednesday for its TYK2 inhibitor, NDI-034858, in moderate-to-severe plaque psoriasis.
Posts
2022 has been marked by the first year of leadership under CEO Joaquin Duato and the anticipated separation of the company’s consumer health business.
A separation of Sandoz via a 100 percent spin-off will create the leading European generics company and a global leader in biosimilars, and a more focused Novartis.
BMS announced that the FDA approved Sotyktu for adults with moderate-to-severe plaque psoriasis, marking this indication’s first oral treatment innovation in nearly a decade.
Pfizer and Roivant Sciences unveiled a new company called Priovant Therapeutics to develop and market new therapies for a wide range of autoimmune diseases with high mortality and morbidity rates.
The U.S. Food and Drug Administration has awarded its first approval in the specific interleukin-23 inhibitor space for Crohn’s disease to AbbVie’s Skyrizi I (risakizumab-rzaa).
Bristol Myers Squibb (BMS) announced late-breaking data Wednesday showing that deucravacitinib, an allosteric tyrosine kinase 2 inhibitor, met the primary endpoint in the treatment of systemic lupus erythematosus.